PG
KERX

PEAK6 Group’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

PEAK6 Group’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-33,000
Closed -$329K – 5861
2015
Q2 		$329K Sell
33,000
-27,160
-45% -$291K ﹤0.01% 3217
2015
Q1 		$766K Buy
+60,160
New +$773K 0.01% 2156

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PEAK6 Group's KERX Position: Q3 2015 in Review

PEAK6 Group sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2015, closing a stake of 33,000 shares — an estimated $329K sold.

PEAK6 Group first reported a position in KERX in Q1 2015 and held it in 2 quarters. The position peaked at $766K in Q1 2015. 138 funds tracked by Wall St. Rank hold KERX as of Q3 2015.

  • PEAK6 Group reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2015 after selling out during the quarter.
  • PEAK6 Group sold 33,000 Keryx Biopharmaceuticals Inc shares in Q3 2015, an estimated $329K.
  • PEAK6 Group first reported a position in Keryx Biopharmaceuticals Inc in Q1 2015 and held it in 2 quarters.
  • PEAK6 Group's Keryx Biopharmaceuticals Inc position peaked at $766K in Q1 2015.
  • 138 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2015.

Based on PEAK6 Group's 13F filing for Q3 2015, filed 16 Nov 2015.